- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Baird stuft Kardigan mit "Outperform" ein - Kursziel 43 US-Dollar | 1 | Investing.com Deutsch | ||
| Mi | Baird initiates Kardigan stock with Outperform rating, $43 target | 1 | Investing.com | ||
| 16.10. | Kardigan stock initiated at Outperform by William Blair on pipeline | 1 | Investing.com | ||
| 16.10. | Kardigan-Aktie: William Blair nimmt Beobachtung mit "Outperform" auf - Pipeline im Fokus | 1 | Investing.com Deutsch | ||
| KARDIGAN Aktie jetzt für 0€ handeln | |||||
| 12.10. | UBS startet Coverage für Kardigan mit Kaufempfehlung - Kardiologie-Pipeline als Kurstreiber | 1 | Investing.com Deutsch | ||
| 30.09. | Kardigan, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Kardigan auf Cantor-Konferenz: Plattformansatz für Herzmedikamente | 1 | Investing.com Deutsch | ||
| 17.08. | Citi agrees to acquire Kard Financial for commerce rewards | 3 | The Paypers | ||
| 14.08. | Citi to acquire US rewards tech company Kard Financial | 4 | FinTech Futures | ||
| 14.08. | Citi To Acquire Kard To Supercharge Personalized Rewards And Commerce Media | 3 | pulse2.com | ||
| 14.08. | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | 997 | AFX News | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| 13.08. | Citi to acquire commerce rewards platform Kard Financial | 4 | Investing.com | ||
| 13.08. | Citigroup übernimmt Commerce-Prämienplattform Kard Financial | 3 | Investing.com Deutsch | ||
| 11.08. | Kardigan, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | 2 | Investing.com | ||
| 13.07. | Kardigan: TD Cowen startet Coverage mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | JPMorgan initiates Kardigan stock with overweight on pipeline | 2 | Investing.com | ||
| 13.07. | Jefferies initiates Kardigan stock with buy rating on cardiology pipeline | 1 | Investing.com | ||
| 13.07. | Jefferies startet Kardigan mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 0,370 | +2,21 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 33,280 | +0,09 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,577 | +1,58 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| IRONWOOD PHARMACEUTICALS | 3,040 | -3,80 % | Ironwood Pharmaceuticals names Tammi Gaskins CEO | ||
| GALECTIN THERAPEUTICS | 2,800 | +4,48 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,385 | +7,43 % | NRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine | ||
| GRACE THERAPEUTICS | 1,930 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 7,910 | 0,00 % | Kazia gains as Guggenheim is latest to initiate at Buy on lead asset | ||
| INMED PHARMACEUTICALS | 1,240 | 0,00 % | InMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance | Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 2,020 | -1,94 % | Eledon Pharmaceuticals, Inc.: Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society | Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,277 | +3,06 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| INVENTIVA | 3,210 | -1,44 % | INVENTIVA: Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting 2026 | Preclinical data showed that balanced PPARa, PPARd and PPAR? activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical... ► Artikel lesen | |
| MEDICINOVA | 1,390 | 0,00 % | MediciNova, Inc.: MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 0,645 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial | MONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| ANBIO BIOTECHNOLOGY | 3,300 | +0,61 % | Anbio Biotechnology - 6-K, Report of foreign issuer |
KARDIGAN INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 12,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KARDIGAN INC finden Sie auf Wallstreet Online.